DOP026 Efficacy and safety of dose escalation to tofacitinib 10 mg BID for patients with ulcerative colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: results from OCTAVE open
B.E. Sands1, A.C. Moss2, A. Armuzzi3*, J.K. Marshall4, J.O. Lindsay5, W.J. Sandborn6, S. Danese7, K. Tsilkos8, N. Lawendy9, H. Zhang9, G.S. Friedman9, G. Chan9, D.W. Krichbaum8, C. Su9
1Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, NY, USA, 2Beth Israel Deaconess Medical Centre, Division of Gastroenterology, Boston, MA, USA, 3Presidio Columbus Fondazione Policlinico Gemelli Università Cattolica, IBD Unit, Rome, Italy, 4McMaster University, Division of Gastroenterology, Department of Medicine, Farncombe Family Digestive Health Research Institute, Hamilton, ON, Canada, 5The Royal London Hospital, Barts Health NHS Trust, Department of Gastroenterology, London, UK, 6University of California San Diego, Division of Gastroenterology, La Jolla, CA, USA, 7Humanitas Research Hospital, IBD Center, Department of Gastroenterology, Rozzano, Milan, Italy, 8Pfizer Inc., New York, NY, USA, 9Pfizer Inc., Collegeville, PA, USA
Tofacitinib is an oral, small-molecule Janus kinase inhibitor that is being investigated for ulcerative colitis (UC). We evaluated efficacy and safety of tofacitinib dose escalation in patients with UC participating in an ongoing, open-label, long-term extension (LTE) study (OCTAVE Open, NCT01470612; data as of July 2016 [efficacy], December 2016 [safety]).
OCTAVE1 included induction (OCTAVE Induction 1 and 2), maintenance (OCTAVE Sustain) and LTE (OCTAVE Open) studies. OCTAVE Open included non-responders from OCTAVE Induction 1 and 2 and patients who completed or experienced treatment failure in OCTAVE Sustain. This analysis included the subpopulation of patients in OCTAVE Open who achieved clinical response following 8 weeks of induction therapy with tofacitinib 10 mg twice daily (BID), entered OCTAVE Sustain receiving tofacitinib 5 mg BID and experienced treatment failure between Week 8 and up to Week 52, and subsequently entered OCTAVE Open and were escalated to tofacitinib 10 mg BID. Treatment failure was defined as increase ≥3 points from maintenance study baseline total Mayo score, plus increase in rectal bleeding subscore and endoscopic subscore (ES) ≥1 point and absolute ES ≥2 after ≥8 weeks of maintenance therapy. We evaluated clinical response, mucosal healing and remission at Months 2 and 12 of OCTAVE Open using non-responder imputation, and evaluated safety throughout the study.
The dose escalation subpopulation comprised 58 patients in OCTAVE Open (out of 914 enrolled in the study). In patients escalated to tofacitinib 10 mg BID, clinical response, mucosal healing and remission rates were, respectively, 58.6%, 41.4% and 34.5% at Month 2, and 68.8%, 60.4% and 52.1% at Month 12 (Table). The safety profile of tofacitinib 10 mg BID in the dose escalation subpopulation was generally consistent with that observed in the overall study population (Table).2
For patients who lost initial clinical response to tofacitinib 10 mg BID induction therapy while on tofacitinib 5 mg BID maintenance therapy, dose escalation back to 10 mg BID recaptured clinical response for most patients by Month 2, and was well-tolerated, with no new safety signals. Interpretation of adverse event rates is limited due to the small sample size.